Analyst Ratings for Neumora Therapeutics (NMRA)
NMRA Rating Summary
NMRA Price Target Summary
- Highest: $18.00 (H.C. Wainwright)
- Lowest: $3.00 (Stifel)
- Average: $9.14
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$9.14 (+202.7%)
* Over Last 12-Mos
Rating Score: 6.4 / 10
Percentile Rank: 68%
Avg. $ Target:
$9.14 (+202.7%)
* Over Last 12-Mos
Rating Score: 6.4 / 10
Percentile Rank: 68%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/17/2026 | William Blair | Myles R. Minter | Upgrade | Outperform (Market Perform) |
N/A (N/A) |
3.20 (3.02) |
-5.63% | Details |
| 1/12/2026 | Leerink Partners | Marc Goodman | New Coverage | Outperform (N/A) |
8.00 (N/A) |
2.33 (3.02) |
29.61% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
